Head and Neck Squamous Cell Carcinoma Clinical Trials in Hat Yai, Changwat Songkhla

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)